XML 30 R14.htm IDEA: XBRL DOCUMENT
v3.25.2

Revenue Recognition | 12 Months Ended
--- | ---
May 31, 2025
Revenue from Contract with Customer [Abstract] |
Revenue Recognition | 2. Revenue Recognition The Company derives revenue from two primary sources — product revenue and service revenue. Product revenue consists primarily of shipments of: • Diagnostic test kits, culture media and related products used by food producers and processors to detect harmful natural toxins, foodborne bacteria, allergens and levels of general sanitation; • Consumable products marketed to veterinarians, retailers, livestock producers and animal health product distributors; and • Rodent control products, disinfectants and insect control products to assist in the control of rodents, insects and disease in and around agricultural, food production and other facilities. Revenues for Neogen’s products are recognized and invoiced when the product is shipped to the customer. Service revenue consists primarily of: • Genomic identification and related interpretive bioinformatic services; and • Other commercial laboratory services. Revenues for Neogen’s genomics and commercial laboratory services are recognized and invoiced when the applicable laboratory service is performed and the results are conveyed to the customer. Payment terms for products and services are generally 30 to 90 days. Contract liabilities represent deposits made by customers before the satisfaction of performance obligation(s) and recognition of revenue. Upon completion of the performance obligation(s) that the Company has with the customer, the liability for the customer deposit is relieved and revenue is recognized. These customer deposits are recorded within deferred revenue on the consolidated balance sheets. Changes in the balances relate primarily to sales of the Company's genomics services and Neogen Analytics. The following table summarizes contract liabilities by period:
|  | Year Ended May 31 , |  |
|  | 2025 |  |  | 2024 |  |
Beginning balance |  | $ | 4,632 |  |  | $ | 4,616 |  |
Additions |  |  | 12,658 |  |  |  | 13,267 |  |
Recognized into revenue |  |  | (11,732 | ) |  |  | (13,251 | ) |
Ending balance |  | $ | 5,558 |  |  | $ | 4,632 |  |
The following table presents disaggregated revenue by major product and service categories for the years ended May 31, 2025, 2024 and 2023:
| Year Ended May 31, |
| 2025 |  | 2024 |  | 2023 |
Food Safety: |  |  |  |  |  |
Natural Toxins & Allergens | $ | 77,058 |  | $ | 82,240 |  | $ | 82,567 |
Bacterial & General Sanitation |  | 164,777 |  |  | 171,217 |  |  | 134,934 |
Indicator Testing, Culture Media & Other |  | 325,915 |  |  | 334,636 |  |  | 267,178 |
Rodent Control, Insect Control & Disinfectants |  | 46,971 |  |  | 42,965 |  |  | 39,655 |
Genomics Services |  | 23,419 |  |  | 24,283 |  |  | 22,463 |
| $ | 638,140 |  | $ | 655,341 |  | $ | 546,797 |
Animal Safety: |  |  |  |  |  |
Life Sciences |  | 6,500 |  |  | 6,515 |  |  | 6,254 |
Veterinary Instruments & Disposables |  | 61,468 |  |  | 65,848 |  |  | 63,843 |
Animal Care & Other |  | 34,654 |  |  | 36,978 |  |  | 39,068 |
Rodent Control, Insect Control & Disinfectants |  | 88,063 |  |  | 88,732 |  |  | 87,423 |
Genomics Services |  | 65,836 |  |  | 70,808 |  |  | 79,062 |
| $ | 256,521 |  | $ | 268,881 |  | $ | 275,650 |
Total Revenue | $ | 894,661 |  | $ | 924,222 |  | $ | 822,447 |

X
- References No definition available. + Details
Name: | us-gaap_RevenueFromContractWithCustomerAbstract
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition The entire disclosure of revenue from contract with customer to transfer good or service and to transfer nonfinancial asset. Includes, but is not limited to, disaggregation of revenue, credit loss recognized from contract with customer, judgment and change in judgment related to contract with customer, and asset recognized from cost incurred to obtain or fulfill contract with customer. Excludes insurance and lease contracts. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 9 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479806/606-10-50-9 Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479806/606-10-50-10 Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 15 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479806/606-10-50-15 Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 12 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479806/606-10-50-12 Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 12 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479806/606-10-50-12 Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 12 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479806/606-10-50-12 Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 12 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479806/606-10-50-12 Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 12 -Subparagraph (e) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479806/606-10-50-12 Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 13 -Subparagraph (b)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479806/606-10-50-13 Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Name Accounting Standards Codification -Topic 606 -Publisher FASB -URI https://asc.fasb.org/606/tableOfContent + Details
Name: | us-gaap_RevenueFromContractWithCustomerTextBlock
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration